skip to main content
Guest
e-Shelf
My Account
Sign out
Sign in
This feature requires javascript
Tags
e-Journals
e-Books
Databases
USP Libraries
Help
Help
Language:
English
Spanish
Portuguese (Brazil)
This feature required javascript
This feature requires javascript
Primo Search
General Search
General Search
Physical Collection
Physical Collections
USP Intelectual Production
USP Production
Search For:
Clear Search Box
Search in:
General Search
Or hit Enter to replace search target
Or select another collection:
Search in:
General Search
Advanced Search
Browse Search
This feature requires javascript
This feature requires javascript
Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support
Rizzieri
, David A ; Chao, Nelson
J
Current opinion in oncology, 1997-09, Vol.9 (5), p.420-427
United States: Lippincott-Raven Publishers
Full text available
Citations
Cited by
View Online
Details
Reviews & Tags
More
Times Cited
This feature requires javascript
Actions
Add to e-Shelf
Remove from e-Shelf
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support
Author:
Rizzieri
, David A
;
Chao, Nelson
J
Subjects:
Antineoplastic Agents - therapeutic use
;
Bone Marrow Purging
;
Dose-Response Relationship, Drug
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Lymphoma, Follicular - therapy
;
Lymphoma, Non-Hodgkin - drug therapy
;
Lymphoma, Non-Hodgkin - therapy
;
Risk Factors
;
Transplantation, Homologous
Is Part Of:
Current opinion in oncology, 1997-09, Vol.9 (5), p.420-427
Notes:
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Description:
Standard therapies for advanced low-grade lymphomas are not likely to provide a cure, prompting the use of more aggressive approaches. Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have a prolonged disease-free survival, although the benefit to overall survival remains unproven. Patients with chemotherapysensitive intermediate- or high-grade relapsed disease have improved survival with high-dose therapy, and those with high-risk disease may benefit from early consolidation while in first remission. Significant questions remain in terms of the proper timing of high-dose therapy, appropriate stratification by risk factors, the value of purging, the role of radiotherapy after transplantation, and the most appropriate source of stem cells for transplantation.
Publisher:
United States: Lippincott-Raven Publishers
Language:
English
Links
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Back to results list
Previous
Result
10
Next
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript
Previous
Home Page
RSS
Feed
Policies
Contact Us
Social Network Logos: 
Social Network Logos: